2020 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
2016 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2015 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2010 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 4
As coordinator: 0
As participant: 4
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2020 | 0 | 9.969.012 | 851.875 | 1 | ||
2016 | 0 | 22.188.522 | 15.000 | 1 | ||
2015 | 0 | 7.993.660 | 454.593 | 1 | ||
2010 | 0 | 11.929.250 | 241.334 | 1 |
Total number of partners: 81
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 81
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2020-01-01 | STRATIFIED HOST-DIRECTED THERAPY FOR DRUG-RESISTANT TUBERCULOSIS: A RANDOMIZED CONTROLLED MULTI-CENTRE TRIAL | DRTB-HDT | participant | 9.969.012 | 10 |
2016-01-01 | European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates | EHVA | participant | 22.188.522 | 43 |
2015-01-01 | Eliciting Mucosal Immunity to Tuberculosis | EMI-TB | participant | 7.993.660 | 14 |
2010-01-01 | Cutaneous and Mucosal HIV Vaccination | CUT'HIVAC | participant | 11.929.250 | 18 |